Dyne Therapeutics (NASDAQ:DYN) Receives “Buy” Rating from Chardan Capital

Dyne Therapeutics (NASDAQ:DYN)‘s stock had its “buy” rating reaffirmed by stock analysts at Chardan Capital in a research report issued on Friday,Benzinga reports. They currently have a $50.00 target price on the stock. Chardan Capital’s target price suggests a potential upside of 273.55% from the stock’s current price.

A number of other brokerages have also recently commented on DYN. Royal Bank of Canada reiterated an “outperform” rating and issued a $45.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, January 14th. HC Wainwright reduced their target price on shares of Dyne Therapeutics from $55.00 to $46.00 and set a “buy” rating for the company in a research report on Friday. Piper Sandler reduced their target price on shares of Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating for the company in a research report on Friday. Robert W. Baird started coverage on shares of Dyne Therapeutics in a research report on Friday, December 13th. They set an “outperform” rating and a $46.00 price objective for the company. Finally, Guggenheim restated a “buy” rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. One analyst has rated the stock with a sell rating, one has given a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Dyne Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $48.64.

Dyne Therapeutics Trading Up 1.6 %

Shares of DYN stock traded up $0.22 during trading hours on Friday, hitting $13.39. The company’s stock had a trading volume of 148,560 shares, compared to its average volume of 2,224,916. The company has a 50 day moving average of $17.19 and a 200 day moving average of $27.93. The stock has a market cap of $1.36 billion, a PE ratio of -3.76 and a beta of 1.11. Dyne Therapeutics has a 12-month low of $12.87 and a 12-month high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. As a group, analysts anticipate that Dyne Therapeutics will post -3.44 earnings per share for the current fiscal year.

Insider Activity

In other Dyne Therapeutics news, SVP Richard William Scalzo sold 1,455 shares of the stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total value of $40,914.60. Following the sale, the senior vice president now directly owns 127,078 shares of the company’s stock, valued at $3,573,433.36. This trade represents a 1.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Oxana Beskrovnaya sold 2,334 shares of the stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total value of $65,632.08. Following the completion of the sale, the insider now directly owns 201,685 shares in the company, valued at $5,671,382.20. This represents a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 6,387 shares of company stock worth $142,789. 20.77% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. GF Fund Management CO. LTD. bought a new position in Dyne Therapeutics during the fourth quarter valued at about $50,000. Neo Ivy Capital Management acquired a new position in shares of Dyne Therapeutics in the 4th quarter valued at $205,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Dyne Therapeutics by 6.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 143,363 shares of the company’s stock valued at $3,378,000 after purchasing an additional 9,029 shares during the period. Voloridge Investment Management LLC acquired a new position in shares of Dyne Therapeutics in the 4th quarter valued at $2,804,000. Finally, Two Sigma Advisers LP boosted its position in shares of Dyne Therapeutics by 25.4% in the 4th quarter. Two Sigma Advisers LP now owns 76,100 shares of the company’s stock valued at $1,793,000 after purchasing an additional 15,400 shares during the period. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.